September 22, 2023
UN Commitment on Tuberculosis Needs Leadership to Match Ambition
Statement from Mel Spigelman, MD, President and CEO of TB Alliance
September 15, 2023
Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
Interim results of operational research in LIFT-TB countries support decision to adopt improved treatment
August 14, 2023
Realizing our “Triple-A Mandate”
TB Alliance is committed to ensuring its products are adopted, available and affordable; here’s how we’ve been working to live up to that promise with our six-month DR-TB cure
August 10, 2023
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
Non-profit drug developer partners with leading manufacturer of medicine in Pakistan
July 26, 2023
Pretomanid’s Addition to the WHO’s Essential Medicine List Enhances Access to All Oral, Six-Month DR-TB Therapy
Statement from Mel Spigelman, MD, CEO, TB Alliance
May 17, 2023
TB Alliance receives up to $3.9M from the Cystic Fibrosis Foundation to further the development of an NTM drug
TB Alliance will advance the research and development of a new compound that could be used to treat infections caused by nontuberculous mycobacteria
May 8, 2023
TB Alliance Statement on United Nations Multi-Stakeholder Hearing on Tuberculosis
Statement from Mel Spigelman, MD, President and CEO, TB Alliance
March 10, 2023